1.
|
Ashkenazi A and Dixit VM: Death receptors:
Signaling and modulation. Science. 281:1305–1308. 1998.
|
2.
|
Wiley SR, Schooley K, Smolak PJ, et al:
Identification and characterization of a new member of the TNF
family that induces apoptosis. Immunity. 3:673–682. 1995.
|
3.
|
Pan G, O’Rourke K, Chinnaiyan AM, et al:
The receptor for the cytotoxic ligand TRAIL. Science. 276:111–113.
1997.
|
4.
|
Sheridan JP, Marsters SA, Pitti RM, et al:
Control of TRAIL-induced apoptosis by a family of signaling and
decoy receptors. Science. 277:818–821. 1997.
|
5.
|
Pan G, Ni J, Wei YF, Yu G, Gentz R and
Dixit VM: An antagonist decoy receptor and a death
domain-containing receptor for TRAIL. Science. 277:815–818.
1997.
|
6.
|
Mulders P, Figlin R, de Kernion JB, et al:
Renal cell carcinoma: Recent progress and future directions. Cancer
Res. 57:5189–5195. 1997.
|
7.
|
Bex A, Haanen JB, Vyth-Dreese FA,
Horenblas S and de Gast GC: Cytokine therapy response as a
selection criterion for cytoreductive nephrectomy in metastatic
renal clear-cell carcinoma of intermediate prognosis. Results and
conclusions from a combined analysis. Urol Int. 80:367–371.
2008.
|
8.
|
Escudier B, Eisen T, Stadler WM, et al:
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J
Med. 356:125–134. 2007.
|
9.
|
Hudes G, Carducci M, Tomczak P, et al:
Temsirolimus, interferon alfa, or both for advanced renal-cell
carcinoma. N Engl J Med. 356:2271–2281. 2007.
|
10.
|
Motzer RJ, Escudier B, Oudard S, et al:
Efficacy of everolimus in advanced renal cell carcinoma: a
double-blind, randomised, placebo-controlled phase III trial.
Lancet. 372:449–456. 2008.
|
11.
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med. 356:115–124. 2007.
|
12.
|
Froehner M, Hakenberg OW and Wirth MP:
Molecular therapy in urologic oncology. Urol Int. 79:1–7. 2007.
|
13.
|
Takeda K, Smyth MJ, Cretney E, et al:
Critical role for tumor necrosis factor-related apoptosis-inducing
ligand in immune surveillance against tumor development. J Exp Med.
195:161–169. 2002.
|
14.
|
Ashkenazi A, Pai RC, Fong S, et al: Safety
and antitumor activity of recombinant soluble Apo2 ligand. J Clin
Invest. 104:155–162. 1999.
|
15.
|
Oya M, Ohtsubo M, Takayanagi A, Tachibana
M, Shimizu N and Murai M: Constitutive activation of nuclear
factor-kappaB prevents TRAIL-induced apoptosis in renal cancer
cells. Oncogene. 20:3888–3896. 2001.
|
16.
|
Walczak H, Miller RE, Ariail K, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
|
17.
|
Zeng Y, Wu XX, Fiscella M, et al:
Monoclonal antibody to tumor necrosis factor-related
apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis
in primary renal cell carcinoma cells in vitro and inhibits
tumor growth in vivo. Int J Oncol. 28:421–430. 2006.
|
18.
|
Macher-Goeppinger S, Aulmann S, Tagscherer
KE, et al: Prognostic value of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell
cancer. Clin Cancer Res. 15:650–659. 2009.
|
19.
|
Roux S, Apetoh L, Chalmin F, et al:
CD4+CD25+ Tregs control the TRAIL-dependent
cytotoxicity of tumor-infiltrating DCs in rodent models of colon
cancer. J Clin Invest. 118:3751–3761. 2008.
|
20.
|
Tecchio C, Huber V, Scapini P, et al:
IFNalpha-stimulated neutrophils and monocytes release a soluble
form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand)
displaying apoptotic activity on leukemic cells. Blood.
103:3837–3844. 2004.
|
21.
|
Tanaka H, Ito T, Kyo T and Kimura A:
Treatment with IFNalpha in vivo up-regulates serum-soluble
TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL
mRNA expressions in neutrophils in chronic myelogenous leukemia
patients. Eur J Haematol. 78:389–398. 2007.
|
22.
|
Perik PJ, Van der Graaf WT, De Vries EG,
et al: Circulating apoptotic proteins are increased in long-term
disease-free breast cancer survivors. Acta Oncol. 45:175–183.
2006.
|